Arax Advisory Partners’s TriSalus Life Sciences TLSI Stock Holding History

Arax Advisory Partners’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Buy	5,847 +1,842	+46%	+$7.32K	﹤0.01%	3762
2026 Q1	$16K	Sell	4,005 -3	-0.1%	-$15	﹤0.01%	2213
2025 Q4	$28K	Sell	4,008 -40	-1%	-$224	﹤0.01%	1932
2025 Q3	$18.8K	Buy	4,048 +40	+1%	+$187	﹤0.01%	2287
2025 Q2	$21.8K	Hold	4,008	–	–	﹤0.01%	1630
2025 Q1	$22.1K	Buy	+4,008	New	+$21.3K	﹤0.01%	1260

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Arax Advisory Partners's TLSI Position: Q2 2026 in Review

Arax Advisory Partners increased its TriSalus Life Sciences (TLSI) stake by 46% in Q2 2026, buying an estimated $7.32K and bringing the position to 5,847 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3762.

Arax Advisory Partners first reported a position in TLSI in Q1 2025 and has held it in 6 quarters since. The position peaked at $28K in Q4 2025. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Arax Advisory Partners held 5,847 shares of TriSalus Life Sciences worth $26.6K as of Q2 2026.
Arax Advisory Partners bought 1,842 TriSalus Life Sciences shares in Q2 2026, an estimated $7.32K.
TriSalus Life Sciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3762 holding.
Arax Advisory Partners first reported a position in TriSalus Life Sciences in Q1 2025 and has held it in 6 quarters since.
Arax Advisory Partners's TriSalus Life Sciences position peaked at $28K in Q4 2025.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.